143
Participants
Start Date
June 30, 2013
Primary Completion Date
December 31, 2018
Study Completion Date
February 28, 2019
RXDX-105
"During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment."
City of Hope, Duarte
University of California Irvine College of Medicine, Irvine
University of California San Diego Moores Cancer Center, San Diego
Lombardi Comprehensive Cancer Center, Georgetown, Washington D.C.
Florida Cancer Center, Sarasota
University Cancer & Blood Center, LLC, Athens
Massachusetts General Hospital/Beth Israel Deaconess Med. Ctr./Dana Farber Cancer Institute, Boston
Henry Ford Health System, Detroit
Karmanos Cancer Center, Detroit
Washington University, St Louis
Memorial Sloan Kettering Cancer Center, New York
Fox Chase Cancer Center, Philadelphia
University of Texas MD Anderson Cancer Center, Houston
University of Washington, Seattle Cancer Care Alliance, Seattle
Hoffmann-La Roche
INDUSTRY